Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-012111
Date:2020-02-18
Issuer: NOVAVAX INC (NVAX)
Original Submission Date:

Reporting Person:

GLENN GREGORY M
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD GAITHERSBURG, MD 20878

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-02-18 S 80 d $264.09 5,165 direct
COMMON STOCK 2021-02-18 S 361 d $265.53 4,804 direct
COMMON STOCK 2021-02-18 S 128 d $266.68 4,676 direct
COMMON STOCK 2021-02-18 S 268 d $268.19 4,408 direct
COMMON STOCK 2021-02-18 S 678 d $269.23 3,730 direct
COMMON STOCK 2021-02-18 S 319 d $269.94 3,411 direct
COMMON STOCK 2021-02-18 S 110 d $271.16 3,301 direct
COMMON STOCK 2021-02-18 S 205 d $272.43 3,096 direct
COMMON STOCK 2021-02-18 S 67 d $273.61 3,029 direct
COMMON STOCK 2021-02-18 S 48 d $274.63 2,981 direct
COMMON STOCK 2021-02-18 S 32 d $276.23 2,949 direct
COMMON STOCK 2021-02-18 S 65 d $278.27 2,884 direct
COMMON STOCK 2021-02-18 S 73 d $279.20 2,811 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person.
f2 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $263.90 to $264.22,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f3 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $265.08 to $266.02,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f4 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $266.44 to $266.96,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f5 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $267.63 to $268.59,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f6 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $268.69 to $269.68,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f7 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $269.75 to $270.24,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f8 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $270.82 to $271.61,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f9 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $271.90 to $272.77,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f10 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $273.54 to $273.67,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f11 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $277.91 to $278.62,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
f12 the reported price is a weighted average price. these shares were sold in multiple transactions at prices ranging from $279.00 to $279.41,inclusive. the reporting person undertakes to provide to novavax, inc., any security holder of novavax, inc., or the staff of the securities andexchange commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.

Elevate your investments